Since 1993, three major events have substantially influenced our management of hypertension. The most important event was the publication in September 1997 of the results of the SYST-EUR trial. 5 This was the first placebo-controlled trial which opted not to use beta-blockers or thiazides as the first-line treatment of hypertension. This trial was largely confirmatory of the beneficial effects of treating isolated systolic hypertension which had so convincingly been shown in the Systolic Hypertension in the Elderly Programme (SHEP), but the first-line drug was a calcium channel blocker, with an angiotensin-converting enzyme (ACE) inhibitor added in where necessary. These 'designer' drugs comprehensively block the effects of angiotensin at the receptor site and should in theory have all the advantages of the ACE inhibitors. However, because of the lack of effect of the sartans on bradykinin metabolism, angioedema and dry irritating cough, which typify ACE inhibition, may be avoided. Whatever else is said about the sartans they do appear to have a remarkably benign side effect profile and in most studies have been shown to be equally as tolerable as placebo tablets.
The third event to unsettle the hypertension world has been the publication from 1995 onwards, of a series of largely retrospective case control studies which suggest that the calcium channel blockers as a group are associated with an adverse outcome in terms of cancer, coronary heart disease, gastrointestinal haemorrhage, perioperative surgical haemorrhage and suicide. [7] [8] [9] [10] [11] It would, however, not be an overstatement to comment that these reports have been controversial. These retrospective case control studies need to be re-examined in the light of the results of the SYST-EUR trial where calcium channel blockers were shown to cause a reduction in the incidence of stroke and coronary end-points with no excess of cancer or haemorrhagic events.
It is apparent from the events listed above that all the guidelines published in 1993 can now be considered to be obsolete. In those days, the sartan group of drugs were not available, the calcium channel blockers seemed to be innocent and we only had one study which convincingly showed that isolated systolic hyptertension was worth treating.
New guidelines are clearly necessary and in November 1997 the Joint National Committee of the National Heart Lung and Blood Institute published their sixth report on prevention, detection, evaluation and treatment of high blood pressure (referred to as JNC-VI) in the Archives of Internal Medicine. 12 JNC-VI is an important document if only because the opinions of the Joint National Committee (JNC) will be very influential in many countries outside North America. These are also the first guidelines to be published following the publication of the calcium channel blocker papers, the development of the sartan group of drugs and the publication of the SYST-EUR trial.
In their introduction, the JNC comment that they had attempted to make the new guidelines more closely related to evidence-based medicine and a risk analysis of individual patients. They provide us with some useful tables with thresholds for treatment in relation not only to the height of blood pressure but also to the overall cardiovascular risk status (Table 1) . Patients with no target organ damage or other cardiovascular risk factors might therefore receive a less aggressive approach than patients who have target organ damage, multiple risk factors and blood pressures which are well into the range where anti-hypertensive drugs are considered mandatory. In their assessment of cardiovascular risk, however, the JNC do perhaps confuse the concept of an optimum blood pressure with that of a blood pressure where treatment is necessary. The implication seems to be that systolic blood pressures between 140-160 mm Hg are under certain circumstances worth treating although there is no trial evidence to suggest that this is the case. In the United Kingdom, we have enough problems trying to persuade clinicians to treat patients with systolic blood pressures consistently in excess of 160 mm Hg without lowering the target even further. Many clinicians will feel unhappy about placing a patient with a systolic blood pressure of, for example, 146 mm Hg on anti-hypertensive drugs. The risk-benefit ratio must surely be finely drawn in such patients.
The new guidelines do produce useful information on the role of the ACE inhibitors on patients with hypertension associated with nephropathy either due to diabetes or to other conditions. In addition the importance of concomitant heart failure is also emphasised. Nevertheless, JNC-VI still comes to the same, basic view (as published in JNC V and the BHS Guidelines) 'that if there are no indications for another type of drug, a diuretic or beta-blocker should be chosen because numerous randomised controlled trials have shown a reduction in morbidity and mortality with these agents'. This suggestion flies in the face of the evidence that the betablocking drugs have been particularly disappointing in terms of coronary prevention and are somewhat less effective in older patients and in patients of Afro-Caribbean origin. Also, only 2 months before JNC-VI was published, we had a randomised con- trolled trial of calcium channel blockers (the SYST-EUR trial) which, in percentage terms, was more impressive than most of the other studies in the prevention of both coronary heart disease and stroke. The authors of JNC-VI were clearly and corporately not over impressed with the retrospective case controlled studies suggesting that calcium channel blockers cause all sorts of horrible diseases. Indeed, it would have been nice to have had some guidance as to the relative importance of retrospective case control studies in comparison with randomised controls trials, especially since the calcium antagonist 'crisis' caused much anxiety and concern amongst patients and their doctors. One could argue that randomised control trials; if they are truly well randomised, are 10 times more powerful and valid than any other sort of study. JNC-VI does seem to draw attention to the relative power of the various papers that they have evaluated but seem to place relatively little importance on the SYST-EUR trial. Perhaps the mere 2 months between the publication of SYST-EUR and the publication of JNC-VI explains this or perhaps a calcium antagonist phobia is hard to purge. Because of the lack of any hard data on longterm outcome data, the sartan group of drugs also receive relatively little attention even though they are rapidly increasing in popularity amongst both doctors and patients. The cynic would even argue that at the end of the day, JNC-VI could be considered to be a rather conservative repetition of earlier versions of these guidelines.
All guidelines committees can be criticised for being either too conservative or too aggressive and JNC-VI does not lack its critics. In their commentary in the Lancet, Furburg and Psarty criticised JNC-VI for being more consensus-based than evidencebased but received a swift repost from one of the authors of the guidelines document. 13, 14 Furberg and Psaty further commented that 'it remains to be seen whether the JNC-VI guidelines will withstand the test of time'.
What then of the other organisations? Rumour has it that the BHS will be producing new guidelines during 1998 but it remains to be seen whether any consensus can be obtained by the Society even in relation to evidence-based medicine. The slavish adherence of the concept of evidence-based medicine is perhaps unfortunate in this respect as there can be good evidence, indifferent evidence and bad evidence. Dr Crippen presumably gave evidence at his trial for the murder of his wife but it is apparent that the jury did not believe him! Since JNC-VI was published, there has been a further controversial study (the Appropriate Blood Pressure Control and Diabetes (ABCD) trial) investigating the value of the calcium channel blocker, nisoldipine, in comparison with enalapril in patients with non-insulin dependent diabetes mellitus. 15 In this study, patients on enalapril fared significantly better than those given nisoldipine. The authors were at pains to point out however, they were not in a position to say whether the differences in outcome were due to beneficial effects of enalapril or harmful effects of the calcium channel blocker. 16 As this is a sub-group analysis of secondary end-points for the main trial in patients with non-insulin dependent diabetes mellitus, the data must therefore be treated with some caution, but the ABCD trial continues to feed the calcium antagonist phobia.
As stated earlier, the guidelines from JNC-VI will be hugely influential worldwide. As seen from the United Kingdom, the guidelines are probably a little disappointing as they do not address in detail the three most important things to have influenced hypertension doctors over the last 5 years. After any major study, be it SYST-EUR or the ABCD trial, there is a time when clinicians need to pause and take stock, listen to each others opinions (be it in hotel bars at international meetings) and hear the data presented on several occasions by speakers with occasionally differing points of view. Only then can a considered opinion emerge and this process probably takes about 12 months. Furburg and Psaty comment that they doubt whether the JNC-VI guidelines will withstand the test of time, but they have these doubts for reasons other than the importance of the result of the SYST-EUR trial or the development of the sartan group of drugs. Perhaps JNC-VI would have been more useful if the officers had opted to delay their deliberations by 6 months or so and perhaps the BHS will find itself in a stronger position having had more time to deliberate, cogitate and regurgitate evidence.
At the end of the day, however, there is unanimity that a very large number of patients are receiving sub-optimal treatment by any criteria. No-one doubts that patients with blood pressures which are consistently greater than 160/90 mm Hg should receive anti-hypertensive medication if their blood pressures do not respond to non-pharmacological manoeuvres. The achievement of this target is long overdue and all too many population surveys show that anti-hypertensive treatment is being withheld from millions of people despite the proven benefits of blood pressure reduction. It is no wonder that many regard the United Kingdom as a 'control group nation' when it comes to hypertension management. Perhaps one way to improve the population treatment of hypertension, where presently only a third are optimally monitored and/or treated, is to do a population-wide randomised placebo controlled trial, where at least 50% will actually get treated and blood pressures monitored carefully in all patients!
